224 related articles for article (PubMed ID: 25304272)
1. Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.
Kainulainen H; Papaioannou KG; Silvennoinen M; Autio R; Saarela J; Oliveira BM; Nyqvist M; Pasternack A; 't Hoen PA; Kujala UM; Ritvos O; Hulmi JJ
Mol Cell Endocrinol; 2015 Jan; 399():131-42. PubMed ID: 25304272
[TBL] [Abstract][Full Text] [Related]
2. Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E171-82. PubMed ID: 23695214
[TBL] [Abstract][Full Text] [Related]
3. Effects of muscular dystrophy, exercise and blocking activin receptor IIB ligands on the unfolded protein response and oxidative stress.
Hulmi JJ; Hentilä J; DeRuisseau KC; Oliveira BM; Papaioannou KG; Autio R; Kujala UM; Ritvos O; Kainulainen H; Korkmaz A; Atalay M
Free Radic Biol Med; 2016 Oct; 99():308-322. PubMed ID: 27554968
[TBL] [Abstract][Full Text] [Related]
4. Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.
Hoogaars WM; Mouisel E; Pasternack A; Hulmi JJ; Relizani K; Schuelke M; Schirwis E; Garcia L; Ritvos O; Ferry A; 't Hoen PA; Amthor H
Hum Gene Ther; 2012 Dec; 23(12):1269-79. PubMed ID: 22894762
[TBL] [Abstract][Full Text] [Related]
5. ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo.
Béchir N; Pecchi E; Vilmen C; Le Fur Y; Amthor H; Bernard M; Bendahan D; Giannesini B
FASEB J; 2016 Oct; 30(10):3551-3562. PubMed ID: 27416839
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial impairment induced by postnatal ActRIIB blockade does not alter function and energy status in exercising mouse glycolytic muscle in vivo.
Béchir N; Pecchi É; Relizani K; Vilmen C; Le Fur Y; Bernard M; Amthor H; Bendahan D; Giannesini B
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E539-49. PubMed ID: 26837807
[TBL] [Abstract][Full Text] [Related]
7. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
[TBL] [Abstract][Full Text] [Related]
8. Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Ma H; Pierre P; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jan; 304(1):E41-50. PubMed ID: 23115080
[TBL] [Abstract][Full Text] [Related]
9. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
10. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
11. Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling.
Alyodawi K; Vermeij WP; Omairi S; Kretz O; Hopkinson M; Solagna F; Joch B; Brandt RMC; Barnhoorn S; van Vliet N; Ridwan Y; Essers J; Mitchell R; Morash T; Pasternack A; Ritvos O; Matsakas A; Collins-Hooper H; Huber TB; Hoeijmakers JHJ; Patel K
J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):662-686. PubMed ID: 30916493
[TBL] [Abstract][Full Text] [Related]
12. A muscle growth-promoting treatment based on the attenuation of activin/myostatin signalling results in long-term testicular abnormalities.
Vaughan D; Mitchell R; Kretz O; Chambers D; Lalowski M; Amthor H; Ritvos O; Pasternack A; Matsakas A; Vaiyapuri S; Huber TB; Denecke B; Mukherjee A; Widera D; Patel K
Dis Model Mech; 2021 Feb; 14(2):. PubMed ID: 33408083
[TBL] [Abstract][Full Text] [Related]
13. Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone.
Iskenderian A; Liu N; Deng Q; Huang Y; Shen C; Palmieri K; Crooker R; Lundberg D; Kastrapeli N; Pescatore B; Romashko A; Dumas J; Comeau R; Norton A; Pan J; Rong H; Derakhchan K; Ehmann DE
Skelet Muscle; 2018 Oct; 8(1):34. PubMed ID: 30368252
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of myostatin reverses muscle fibrosis through apoptosis.
Bo Li Z; Zhang J; Wagner KR
J Cell Sci; 2012 Sep; 125(Pt 17):3957-65. PubMed ID: 22685331
[TBL] [Abstract][Full Text] [Related]
15. Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice.
Fakhfakh R; Lee SJ; Tremblay JP
Cell Transplant; 2012; 21(7):1419-30. PubMed ID: 22449443
[TBL] [Abstract][Full Text] [Related]
16. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.
Nakatani M; Takehara Y; Sugino H; Matsumoto M; Hashimoto O; Hasegawa Y; Murakami T; Uezumi A; Takeda S; Noji S; Sunada Y; Tsuchida K
FASEB J; 2008 Feb; 22(2):477-87. PubMed ID: 17893249
[TBL] [Abstract][Full Text] [Related]
17. Gene expression in mdx mouse muscle in relation to age and exercise: aberrant mechanical-metabolic coupling and implications for pre-clinical studies in Duchenne muscular dystrophy.
Camerino GM; Cannone M; Giustino A; Massari AM; Capogrosso RF; Cozzoli A; De Luca A
Hum Mol Genet; 2014 Nov; 23(21):5720-32. PubMed ID: 24916377
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.
Rahimov F; King OD; Warsing LC; Powell RE; Emerson CP; Kunkel LM; Wagner KR
Physiol Genomics; 2011 Apr; 43(8):398-407. PubMed ID: 21266502
[TBL] [Abstract][Full Text] [Related]
19. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.
Bayarsaikhan O; Kawai N; Mori H; Kinouchi N; Nikawa T; Tanaka E
J Nutr Sci Vitaminol (Tokyo); 2017; 63(4):244-248. PubMed ID: 28978871
[TBL] [Abstract][Full Text] [Related]
20. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.
Amthor H; Hoogaars WM
Curr Gene Ther; 2012 Jun; 12(3):245-59. PubMed ID: 22554312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
